Cross-sectional study of therapy-related expectations/concerns of patients with metastatic renal cell carcinoma and physicians in Japan.

Autor: Kimura G; Department of Urology, Nippon Medical School Hospital, Tokyo, Japan., Fujii Y; Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan., Osawa T; Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan., Uchitomi Y; Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tokyo, Japan., Honda K; Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan., Kondo M; Department of Nursing, National Cancer Center Hospital East, Kashiwa, Japan., Otani A; Department of Nursing, National Cancer Center Hospital East, Kashiwa, Japan., Wako T; Department of Pharmacy, Nippon Medical School Hospital, Tokyo, Japan., Kawai D; Eisai Co., Ltd., Tokyo, Japan., Mitsuda Y; Eisai Co., Ltd., Tokyo, Japan., Sakashita N; Medilead, Inc., Tokyo, Japan., Shinohara N; Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2024 Jun; Vol. 13 (11), pp. e7196.
DOI: 10.1002/cam4.7196
Abstrakt: Objective: To achieve patient-centricity in metastatic renal cell carcinoma (mRCC) treatment, it is essential to clarify the differences in perspectives between patients and physicians. This cross-sectional analysis of a web survey aimed to clarify the differences in expectations and concerns between mRCC patients and physicians regarding systemic mRCC therapy in Japan.
Methods: Surveys from 83 patients and 165 physicians were analyzed.
Results: The top three most significant differences in expectations of systemic therapy between patients and physicians (patient-based physician value) were "Chance of achieving treatment-free status" (-30.1%, p < 0.001), "Longer survival" (+25.8%, p < 0.001), and "Chance of eliminating all evidence of disease" (-25.6%, p < 0.001). The top three most significant differences in concerns for systemic therapy between patients and physicians (patient-based physician value) were "Lack of efficacy" (+36.1%, p < 0.001), "Lack of knowledge of treatment" (-28.2%, p < 0.001), and "Daily activities affected by side effects" (+22.3%, p < 0.001). Diarrhea, fatigue/malaise, and nausea/vomiting were patients' most distressing adverse events; 50.6% of patients had difficulty telling their physicians about adverse events such as fatigue, anxiety, and depression.
Conclusions: This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient-centricity in systemic treatment for mRCC.
(© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje